6505--Request for Infromation - U.S. Produced Pharmaceuticals
Active
36E79726Q0002FederalResponse Deadline
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
Show more
The Department of Veterans Affairs (VA) issued a Request for Information (RFI) to gather market data on pharmaceuticals produced in the United States, in alignment with Executive Order 13944, aimed at strengthening domestic pharmaceutical supply chains and reducing dependency on foreign sources. The VA is particularly interested in identifying U.S.-produced pharmaceuticals that meet the definition outlined in the executive order, meaning both the critical inputs and finished drug products are manufactured or processed within the U.S. Respondents are asked to provide detailed information concerning the origin of ingredients, manufacturing processes, and supply capabilities. Additionally, companies must demonstrate compliance with specific requirements, such as possessing a unique National Drug Code (NDC) labeler code, securing manufacturer supply commitments, and having agreements in place with Pharmaceutical Prime Vendors used by the VA and DoD. The RFI also requests that companies specify their business size under NAICS code 325412 and indicate if they qualify as small businesses producing at least half of their pharmaceutical products domestically. Information on contract term preferences, readiness to supply within 60 days of award, and any reasons for potential non-participation is also sought. This market research opportunity does not guarantee a future solicitation or contract award and is intended solely for information gathering to inform potential procurement actions that may include a base one-year contract with four one-year options, facilitating supply continuity. Responses are due by June 24, 2026, and should be submitted to designated VA contacts.
General Info
VA seeks US-made pharmaceuticals info to strengthen supply chains, ensure compliance, and inform contracts.
Agency
Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)
NAICS
325412 - Pharmaceutical Preparation Manufacturing View NAICS
Place of Performance
ILSet-Aside
NONE
Timeline
PhaseSources Sought
Response Deadline
Organization & Contact Information
Show more
AgencyDepartment Of Veterans Affairs → Nac Pharmaceuticals (36E797)
Contacts1 person available
OfficeHINES, IL, 60141, USA
Organization / Agency
Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)
Office AddressHINES, IL, 60141, USA
Contacts
Full Description
Show more
REQUEST FOR INFORMATION
Page 4 of 4
U.S. Department of Veterans Affairs
U.S. Produced Pharmaceuticals
Request for Information
Company Name: _________________________
Pursuant to Executive Order (EO) 13944, the Department of Veterans Affairs (VA) is conducting market research to identify sources of U.S. Produced Pharmaceuticals. At this time, VA is seeking to collect information. There is no guarantee that a solicitation will be issued or that any future solicitation would include all of the products attached to this questionnaire. VA understands that many pharmaceuticals rely on ingredients from all over the world. While worldwide supply chains create cost efficiencies, they create potential vulnerabilities and disruptions for the U.S. supply chain, which can put patient safety at risk. This market research seeks information necessary to assess whether procurement opportunities for U.S. produced pharmaceuticals exist that can mitigate these risks. VA s highest priority is identifying pharmaceuticals that fully qualify as U.S.-Produced under EO 13944; however, VA also places significant value on products that incorporate any U.S. manufacturing activity, including domestic production of critical inputs, intermediate steps, or final processing. Specifically, VA is seeking to identify pharmaceuticals that are produced in the U.S., as defined in EO 13944 (August 6, 2020)
An Essential Medicine or Medical Countermeasure is produced in the United States if the Critical Inputs used to produce the Essential Medicine or Medical Countermeasures are produced in the United States and if the Finished Drug Product or Finished Device, are manufactured, prepared, propagated, compounded, or processed, as those terms are defined in section 360(a)(1) of title 21, United States Code, in the United States. Exec. Order No. 13944, 85 FR 49929, 49933 (August 6, 2020) Pharmaceuticals of particular interest are listed on Attachment 1.
Please complete all columns in yellow. For the columns requesting the origin of various ingredients and components, please indicate the origin country. This information will allow VA to verify whether the pharmaceutical is wholly U.S.-produced, consistent with EO 13944 and the definition provided above. Please provide any additional information about your company s product or your company s understanding of the market conditions/availability of the product in general in the comments column. See the definitions tab of the spreadsheet for further information about each category.
Please also provide a response to the following:
Is your Company able to meet the following minimum requirements: National Drug Code (NDC): Offerors shall provide a separate and distinct eleven-digit NDC number unique to the offeror (e.g., 00012-3456-78) for each product proposed. The first five numbers of the eleven-digit NDC number (known as the labeler code) for each product proposed shall identify the offeror. Additionally, the successful offeror/contractor s label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. Does your company have a unique NDC (Labeler Code)? _____________
If the offeror is not the manufacturer of the offered items, the offeror shall submit a letter of commitment from the manufacturer to the offeror which will assure the offeror a source of supply sufficient to satisfy the Government's requirements for the contract period. As noted, this may include that each offeror will maintain at least six months of stock for each awarded pharmaceutical.
Name of Manufacturer: _________________
Would you be able to provide a letter of commitment from the manufacturer for all pharmaceuticals that your company is interested in offering? _____________
Pharmaceutical Prime Vendor: All Ordering Activities under the Department of Veterans Affairs and Department of Defense acquire their pharmaceutical requirements through their Pharmaceutical Prime Vendor Program (PPV). The contractor shall ensure that chargeback agreements with the PPVs have been executed with sufficient time to permit the PPVs to begin timely distribution of Government orders, if an award is made. Does your company currently have a business-to-business agreement with the PPVs?_________
Under NAICS code 325412, is your company size (check one): Large Business ______ Small Business ______
If a small business, does your company manufacture (measure, weigh, mix, and compound) at least 50% of any or all of the products?_________
Please explain below what length of contract your company would be interested in. VA s goal is to establish a contract with a one-year base period plus four one-year option periods, which provide our customers with continuity and consistency of product by allowing long-term purchases of your product. _____________________________________________________________________
______________________________________________________________________
______________________________________________________________________
If an award were to be made based on the above requirements, would your company be able to begin supplying the product in the estimated quantities within 60 days of the contract award date? If not, please provide an estimated timeframe to prepare, providing any relevant details.
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
If your company is uninterested or incapable in/of participating, please respond and provide as much background information possible. This aids our market research for future procurements.
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
Please provide your responses and completed spreadsheet to Diana.Martinez1@va.gov, Teresa.Hussain@va.gov, and Nicholas.McGregor@va.gov. If you could provide your responses to by next Thursday, June 24, 2026, it would be greatly appreciated. Please address all questions to the names noted above.
DISCLAIMER This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI.
U.S. Produced Pharmaceuticals
Request for Information
Company Name: _________________________
Pursuant to Executive Order (EO) 13944, the Department of Veterans Affairs (VA) is conducting market research to identify sources of U.S. Produced Pharmaceuticals. At this time, VA is seeking to collect information. There is no guarantee that a solicitation will be issued or that any future solicitation would include all of the products attached to this questionnaire. VA understands that many pharmaceuticals rely on ingredients from all over the world. While worldwide supply chains create cost efficiencies, they create potential vulnerabilities and disruptions for the U.S. supply chain, which can put patient safety at risk. This market research seeks information necessary to assess whether procurement opportunities for U.S. produced pharmaceuticals exist that can mitigate these risks. VA s highest priority is identifying pharmaceuticals that fully qualify as U.S.-Produced under EO 13944; however, VA also places significant value on products that incorporate any U.S. manufacturing activity, including domestic production of critical inputs, intermediate steps, or final processing. Specifically, VA is seeking to identify pharmaceuticals that are produced in the U.S., as defined in EO 13944 (August 6, 2020)
An Essential Medicine or Medical Countermeasure is produced in the United States if the Critical Inputs used to produce the Essential Medicine or Medical Countermeasures are produced in the United States and if the Finished Drug Product or Finished Device, are manufactured, prepared, propagated, compounded, or processed, as those terms are defined in section 360(a)(1) of title 21, United States Code, in the United States. Exec. Order No. 13944, 85 FR 49929, 49933 (August 6, 2020) Pharmaceuticals of particular interest are listed on Attachment 1.
Please complete all columns in yellow. For the columns requesting the origin of various ingredients and components, please indicate the origin country. This information will allow VA to verify whether the pharmaceutical is wholly U.S.-produced, consistent with EO 13944 and the definition provided above. Please provide any additional information about your company s product or your company s understanding of the market conditions/availability of the product in general in the comments column. See the definitions tab of the spreadsheet for further information about each category.
Please also provide a response to the following:
Is your Company able to meet the following minimum requirements: National Drug Code (NDC): Offerors shall provide a separate and distinct eleven-digit NDC number unique to the offeror (e.g., 00012-3456-78) for each product proposed. The first five numbers of the eleven-digit NDC number (known as the labeler code) for each product proposed shall identify the offeror. Additionally, the successful offeror/contractor s label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. Does your company have a unique NDC (Labeler Code)? _____________
If the offeror is not the manufacturer of the offered items, the offeror shall submit a letter of commitment from the manufacturer to the offeror which will assure the offeror a source of supply sufficient to satisfy the Government's requirements for the contract period. As noted, this may include that each offeror will maintain at least six months of stock for each awarded pharmaceutical.
Name of Manufacturer: _________________
Would you be able to provide a letter of commitment from the manufacturer for all pharmaceuticals that your company is interested in offering? _____________
Pharmaceutical Prime Vendor: All Ordering Activities under the Department of Veterans Affairs and Department of Defense acquire their pharmaceutical requirements through their Pharmaceutical Prime Vendor Program (PPV). The contractor shall ensure that chargeback agreements with the PPVs have been executed with sufficient time to permit the PPVs to begin timely distribution of Government orders, if an award is made. Does your company currently have a business-to-business agreement with the PPVs?_________
Under NAICS code 325412, is your company size (check one): Large Business ______ Small Business ______
If a small business, does your company manufacture (measure, weigh, mix, and compound) at least 50% of any or all of the products?_________
Please explain below what length of contract your company would be interested in. VA s goal is to establish a contract with a one-year base period plus four one-year option periods, which provide our customers with continuity and consistency of product by allowing long-term purchases of your product. _____________________________________________________________________
______________________________________________________________________
______________________________________________________________________
If an award were to be made based on the above requirements, would your company be able to begin supplying the product in the estimated quantities within 60 days of the contract award date? If not, please provide an estimated timeframe to prepare, providing any relevant details.
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
If your company is uninterested or incapable in/of participating, please respond and provide as much background information possible. This aids our market research for future procurements.
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
Please provide your responses and completed spreadsheet to Diana.Martinez1@va.gov, Teresa.Hussain@va.gov, and Nicholas.McGregor@va.gov. If you could provide your responses to by next Thursday, June 24, 2026, it would be greatly appreciated. Please address all questions to the names noted above.
DISCLAIMER This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI.